Skip to Content
Merck
  • Characterization of the phase behaviour of a novel polymerizable lyotropic ionic liquid crystal.

Characterization of the phase behaviour of a novel polymerizable lyotropic ionic liquid crystal.

Physical chemistry chemical physics : PCCP (2015-08-15)
Nicolas Goujon, Maria Forsyth, Ludovic F Dumée, Gary Bryant, Nolene Byrne
ABSTRACT

The development of new polymerizable lyotropic liquid crystals (LLCs) utilizing charged amphiphilic molecules such as those based on long chain imidazolium compounds, is a relatively new design direction for producing robust membranes with controllable nano-structures. Here we have developed a novel polymerizable ionic liquid based LLC, 1-hexadecyl-3-methylimidazolium acrylate (C16mimAcr), where the acrylate anion acts as the polymerizable moiety. The phase behaviour of the C16mimAcr upon the addition of water was characterized using small and wide angle X-ray scatterings, differential scanning calorimetry and polarized optical microscopy. We compare the phase behaviour of this new polymerizable LLC to that of the well known LLC chloride analogue, 1-hexadecyl-3-methylimidazolium chloride (C16mimCl). We find that the C16mimAcr system has a more complex phase behaviour compared to the C16mimCl system. Additional lyotropic liquid crystalline mesophases such as hexagonal phase (H1) and discontinuous cubic phase (I1) are observed at 20 °C for the acrylate system at 50 and 65 wt% water respectively. The appearance of the hexagonal phase (H1) and discontinuous cubic phase (I1) for the acrylate system is likely due to the strong hydrating nature of the acrylate anion, which increases the head group area. The formation of these additional mesophases seen for the acrylate system, especially the hexagonal phase (H1), coupled with the polymerization functionality offers great potential in the design of advanced membrane materials with selective and anisotropic transport properties.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
1-Methylimidazole, ReagentPlus®, 99%
Sigma-Aldrich
1-Chlorohexadecane, 95%
Sigma-Aldrich
1-Methylimidazole, ≥99%, purified by redistillation
Sigma-Aldrich
Acrylic acid, anhydrous, contains 200 ppm MEHQ as inhibitor, 99%